CO6351732A2 - Tratamiento de atrofia vaginal en mujeres con riesgo de patologia tumoral - Google Patents
Tratamiento de atrofia vaginal en mujeres con riesgo de patologia tumoralInfo
- Publication number
- CO6351732A2 CO6351732A2 CO11015194A CO11015194A CO6351732A2 CO 6351732 A2 CO6351732 A2 CO 6351732A2 CO 11015194 A CO11015194 A CO 11015194A CO 11015194 A CO11015194 A CO 11015194A CO 6351732 A2 CO6351732 A2 CO 6351732A2
- Authority
- CO
- Colombia
- Prior art keywords
- women
- treatment
- risk
- vaginal atrophy
- tumor pathology
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 206010003694 Atrophy Diseases 0.000 title 1
- 230000037444 atrophy Effects 0.000 title 1
- 230000007170 pathology Effects 0.000 title 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 abstract 2
- 229960001348 estriol Drugs 0.000 abstract 2
- 229940011871 estrogen Drugs 0.000 abstract 2
- 239000000262 estrogen Substances 0.000 abstract 2
- 206010071018 Urogenital atrophy Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere al uso de estriol en la preparación de una formulación farmacéutica de administración vaginal con la capacidad de auto limitar la absorción de estriol, para la prevención y/o el tratamiento de atrofia urogenital en mujeres, teniendo dichas mujeres una alta probabilidad de desarrollar un tumor estrógeno-dependiendo o que padecen o han padecido un tumor estrógeno-dependiente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200802384A ES2344673B1 (es) | 2008-08-07 | 2008-08-07 | Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral. |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6351732A2 true CO6351732A2 (es) | 2011-12-20 |
Family
ID=41012001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11015194A CO6351732A2 (es) | 2008-08-07 | 2011-02-09 | Tratamiento de atrofia vaginal en mujeres con riesgo de patologia tumoral |
Country Status (22)
Country | Link |
---|---|
US (1) | US9114143B2 (es) |
EP (1) | EP2328589B1 (es) |
JP (1) | JP6207118B2 (es) |
KR (1) | KR101790652B1 (es) |
CN (1) | CN102170886A (es) |
BR (1) | BRPI0917265A2 (es) |
CA (1) | CA2732877C (es) |
CL (1) | CL2011000252A1 (es) |
CO (1) | CO6351732A2 (es) |
CY (1) | CY1120962T1 (es) |
DK (1) | DK2328589T3 (es) |
ES (2) | ES2344673B1 (es) |
HR (1) | HRP20182020T1 (es) |
HU (1) | HUE041377T2 (es) |
LT (1) | LT2328589T (es) |
MX (1) | MX336154B (es) |
PE (1) | PE20110682A1 (es) |
PL (1) | PL2328589T3 (es) |
PT (1) | PT2328589T (es) |
RU (1) | RU2504381C2 (es) |
SI (1) | SI2328589T1 (es) |
WO (1) | WO2010015718A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3787633A1 (en) * | 2018-05-02 | 2021-03-10 | Pantarhei Oncology B.V. | Treatment of advanced estrogen receptor positive breast cancer |
CN110151680A (zh) * | 2019-04-10 | 2019-08-23 | 重庆医药高等专科学校 | 雌三醇凝胶产品及制备方法 |
CN114588252A (zh) * | 2022-04-08 | 2022-06-07 | 暨南大学附属第一医院(广州华侨医院) | 一种用于缓解阴道萎缩和干燥症的组合物及其应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1866M (fr) * | 1961-04-07 | 1963-06-17 | Vismara Francesco Spa | Nouveaux éthers des hormones oestrogenes. |
US4436738A (en) * | 1982-03-15 | 1984-03-13 | Mead Johnson & Company | Stabilized estradiol cream composition |
WO1985002092A1 (en) | 1983-11-14 | 1985-05-23 | Bio-Mimetics Inc. | Bioadhesive compositions and methods of treatment therewith |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
WO1991006289A1 (en) | 1989-10-31 | 1991-05-16 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
DE69014081T2 (de) | 1989-10-31 | 1995-03-30 | Columbia Laboratories, Inc., Miami, Fla. | Mittel zur Feuchthaltung vaginalen Gewebes. |
US5340586A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
IL110024A (en) * | 1994-06-15 | 1998-04-05 | Yissum Res Dev Co | Controlled release oral drug delivery system containing hydrogel- forming polymer |
US5667492A (en) | 1994-10-07 | 1997-09-16 | Columbia Laboratories, Inc. | Use and composition of an anti-sexually transmitted diseases formulation |
AT408067B (de) | 1995-03-17 | 2001-08-27 | Gebro Pharma Gmbh | Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung |
US5741525A (en) | 1995-10-24 | 1998-04-21 | Marshall University Research Corporation | Vaginal pharmaceutical hydrogen peroxide composition |
IT1275816B1 (it) | 1995-10-27 | 1997-10-17 | Montefarmaco Spa | Composizioni farmaceutiche solide per uso vaginale |
AU714797B2 (en) | 1996-06-14 | 2000-01-13 | Mcneil-Ppc, Inc. | Moisture containing compositions that are spreadable onto and adherable to biomembranes, methods of making and use thereof |
IT1284874B1 (it) | 1996-08-02 | 1998-05-22 | Farmigea Spa | Complessi bioadesivi di polycarbophil e farmaci antifungini o antiprotozoari azolici |
US5942243A (en) * | 1996-11-12 | 1999-08-24 | Polytherapeutics, Inc. | Mucoadhesive compositions for administration of biologically active agents to animal tissue |
CA2271843A1 (en) | 1996-11-14 | 1998-05-22 | Lipomedica Ehf. | Topical formulations containing as a therapeutic active agent fatty acids or fatty alcohols or monoglyceride derivatives thereof for treating of mucosa infections |
DE69819748T2 (de) | 1997-09-12 | 2004-09-30 | Columbia Laboratories (Bermuda) Ltd. | Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen |
US6159491A (en) | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
PT1154793E (pt) | 1999-02-26 | 2010-12-21 | Novartis Vaccines & Diagnostic | Utilização de bioadesivos e adjuvantes para a administração de antigénios nas mucosas |
UA74168C2 (uk) | 1999-10-05 | 2005-11-15 | Коламбіа Леборетеріс (Бермуда) Лімітед | Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу |
AU778498B2 (en) | 1999-10-22 | 2004-12-09 | Lif-Hlaup Ehf. Bio-Gels Pharmaceuticals Inc. | Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
AU2001282064B2 (en) | 2000-08-03 | 2007-02-01 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US7709026B2 (en) | 2001-10-29 | 2010-05-04 | Columbia Laboratories, Inc. | Low concentration of peroxide for treating or preventing vaginal infections |
TWI336627B (en) * | 2003-05-23 | 2011-02-01 | Organon Nv | Drug delivery system,and use and manufacturing method thereof |
ES2237298B1 (es) * | 2003-07-16 | 2006-11-01 | Italfarmaco, S.A. | Formulaciones mucoadhesivas semisolidas. |
BRPI0614625A2 (pt) | 2005-08-12 | 2011-04-12 | Drugtech Corp | composição farmacêutica que compreende pelo menos um composto estrogênico, sistema de distribuição de estrogênio vaginal, uso de uma composição e kit que compreende uma pluralidade de cremes vaginais |
US20090124584A1 (en) * | 2005-12-16 | 2009-05-14 | Lyle Corporate Development, Inc. | Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen |
EP1971325A2 (en) * | 2005-12-27 | 2008-09-24 | Duramed Pharmaceuticals, Inc. | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
CN101405006A (zh) * | 2006-01-20 | 2009-04-08 | 梨树医药公司 | 治疗萎缩性阴道炎的方法 |
EP1872775A1 (en) | 2006-06-29 | 2008-01-02 | Polichem S.A. | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders |
WO2008089405A1 (en) | 2007-01-19 | 2008-07-24 | Neurosci, Inc. | Composition of multiple hormones delivered vaginally in a single cream |
ES2310968B1 (es) * | 2007-06-25 | 2010-02-08 | Italfarmaco, S.A. | Uso de estriol en bajas dosis. |
-
2008
- 2008-08-07 ES ES200802384A patent/ES2344673B1/es active Active
-
2009
- 2009-08-07 JP JP2011521599A patent/JP6207118B2/ja active Active
- 2009-08-07 KR KR1020117005341A patent/KR101790652B1/ko active IP Right Grant
- 2009-08-07 LT LTEP09781641.7T patent/LT2328589T/lt unknown
- 2009-08-07 MX MX2011001382A patent/MX336154B/es unknown
- 2009-08-07 RU RU2011108548/15A patent/RU2504381C2/ru active
- 2009-08-07 PT PT09781641T patent/PT2328589T/pt unknown
- 2009-08-07 BR BRPI0917265A patent/BRPI0917265A2/pt not_active Application Discontinuation
- 2009-08-07 CN CN2009801393857A patent/CN102170886A/zh active Pending
- 2009-08-07 US US13/057,775 patent/US9114143B2/en active Active
- 2009-08-07 DK DK09781641.7T patent/DK2328589T3/en active
- 2009-08-07 SI SI200931907T patent/SI2328589T1/sl unknown
- 2009-08-07 CA CA2732877A patent/CA2732877C/en active Active
- 2009-08-07 PL PL09781641T patent/PL2328589T3/pl unknown
- 2009-08-07 ES ES09781641T patent/ES2700614T3/es active Active
- 2009-08-07 HU HUE09781641A patent/HUE041377T2/hu unknown
- 2009-08-07 WO PCT/EP2009/060307 patent/WO2010015718A1/en active Application Filing
- 2009-08-07 EP EP09781641.7A patent/EP2328589B1/en active Active
- 2009-08-07 PE PE2011000133A patent/PE20110682A1/es not_active Application Discontinuation
-
2011
- 2011-02-04 CL CL2011000252A patent/CL2011000252A1/es unknown
- 2011-02-09 CO CO11015194A patent/CO6351732A2/es not_active Application Discontinuation
-
2018
- 2018-11-30 HR HRP20182020TT patent/HRP20182020T1/hr unknown
- 2018-12-07 CY CY181101305T patent/CY1120962T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI0917265A2 (pt) | 2015-11-10 |
SI2328589T1 (sl) | 2019-02-28 |
KR101790652B1 (ko) | 2017-11-20 |
US9114143B2 (en) | 2015-08-25 |
CA2732877A1 (en) | 2010-02-11 |
CA2732877C (en) | 2017-04-18 |
CN102170886A (zh) | 2011-08-31 |
ES2344673A1 (es) | 2010-09-02 |
RU2504381C2 (ru) | 2014-01-20 |
PE20110682A1 (es) | 2011-09-28 |
DK2328589T3 (en) | 2018-12-10 |
RU2011108548A (ru) | 2012-09-20 |
HUE041377T2 (hu) | 2019-05-28 |
ES2344673B1 (es) | 2011-05-03 |
WO2010015718A1 (en) | 2010-02-11 |
HRP20182020T1 (hr) | 2019-01-25 |
MX336154B (es) | 2016-01-11 |
CL2011000252A1 (es) | 2011-11-18 |
CY1120962T1 (el) | 2019-12-11 |
JP2011529951A (ja) | 2011-12-15 |
JP6207118B2 (ja) | 2017-10-04 |
KR20110045041A (ko) | 2011-05-03 |
MX2011001382A (es) | 2011-03-29 |
PL2328589T3 (pl) | 2019-05-31 |
PT2328589T (pt) | 2018-12-18 |
ES2700614T3 (es) | 2019-02-18 |
LT2328589T (lt) | 2019-01-10 |
EP2328589A1 (en) | 2011-06-08 |
US20110183950A1 (en) | 2011-07-28 |
EP2328589B1 (en) | 2018-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP099826A (es) | Uso de estriol en bajas dosis | |
CY1120879T1 (el) | Πολλαπλου συστατικου βιοδραστικος ενδοκολπικος δακτυλιος | |
CL2017000829A1 (es) | Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino. | |
CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
DOP2007000102A (es) | Arilimidazolonas y ariltriazolona sustituidas asi como su uso | |
DOP2014000260A (es) | Compuestos d-aminoácidos para enfermedad hepática | |
CL2008001855A1 (es) | Compuestos ciclicos condensados derivados del boro; composicion farmaceutica; y uso en el tratamiento y/o prevencion de una enfermedad infecciosa. | |
CR20110091A (es) | Anticuerpos neutralizantes de citomegalovirus humano y uso de los mismos | |
BRPI0519242A2 (pt) | uso derivados de 1-aminociclohexano para o tratamento de esclerose méltipla, instabilidade emocional e paralisia pseudobulbar | |
CU20130134A7 (es) | Uso de 2,3- dihidroimidazo [1,2 - c] quinazolinas sustituidas | |
GT200900090A (es) | Uso de valerato de estradiol o 17b-estradiol en combinacion con dienogest en una terapia oral para mantener y/o incrementar la libido femenina | |
CL2012002551A1 (es) | Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor. | |
CL2011002548A1 (es) | Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica. | |
ECSP088889A (es) | Forma nueva de administración de racecadotril | |
CL2011003327A1 (es) | Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales. | |
BR112012013164A2 (pt) | composições farmacêuticas para o estímulo de células-tronco | |
ES2524385R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
CO6351732A2 (es) | Tratamiento de atrofia vaginal en mujeres con riesgo de patologia tumoral | |
BR112012015386B8 (pt) | composição oftálmica tópica | |
CL2012001940A1 (es) | Composiciones que comprenden extractos de andrographis paniculata combinados con extractos de ginkgo biloba complejados con fosfolípidos; y su uso en la preparación de un medicamento para el tratamiento de alzheimer y esclerosis múltiple. | |
ECSP12011951A (es) | Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria | |
CL2010001594A1 (es) | Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida. | |
BR112014016804A8 (pt) | composições, métodos de uso e métodos de tratamento | |
ECSP11010870A (es) | Tratamiento de atrofia vaginal en mujeres con riesgo de patología tumoral | |
CO6382128A2 (es) | Tratamiento de atrofia vaginal en mujeres con riesgo de patologia cardiovascular |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |